FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Hepatitis B infects over 40 million people in India
Almost 300 million people globally have chronic hepatitis B
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.
The approval of this important test marks the 14th IVD to receive clearance by the CDSCO, and strengthens the company’s foundation for future growth
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Subscribe To Our Newsletter & Stay Updated